092040.KQ
Amicogen, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 986.00
+2.18%Year over year
Reported trailing growth
- Revenue
- -60.4%
- EBITDA
- +60.5%
- EBIT
- -18.6%
- EPS
- +65.7%
- Free cash flow
- +96.1%
- Operating cash flow
- +97.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -33.7%
- EBITDA
- +78.2%
- EBIT
- —
- Net income
- +43.2%
- EPS
- +43.9%
- Free cash flow
- +55.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026